Wnt 길항제 유전자 다형성과 호르몬 치료 후 전혈세포에서의 Osteoprotegerin 및 Soluble Receptor Activator of NF-kB Ligand 생산 변화 양상 사이의 연관성

키워드

참고문헌 (31)

1. Hofbauer LC, "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption", J Bone Miner Res, 15, pp.2~12 (2000)
2. Jones DH, "Role of RANKL and RANK in bone loss and arthritis", Ann Rheum Dis, 61, pp.32~39 (2002)
3. Rogers A, "Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand:clinical utility in metabolic bone disease assessment", J Clin Endocrinol Metab, 90, pp.6323~6331 (2005)
4. Westendorf JJ, "Wnt signaling in osteoblasts and bone diseases", Gene, 341, pp.19~39 (2004)
5. Bodine PV, "Wnt signaling and osteoblasotogenesis", Rev Endocr Metab Disord, 7, pp.33~39 (2006)
6. Baron R, "Targeting the Wnt", β-catenin pathway to regulate bone formation in the adult skeleton, 2007, pp.148, 2635~2643
7. Spencer GJ, "Wnt signaling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro", J Cell Sci, 119, pp.1283~1296 (2006)
8. Bovolenta P, "Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease", J Cell Sci, 121, pp.737~746 (2008)
9. Kawano Y, "Secreted antagonists of the Wnt signaling pathway", J Cell Sci, 116, pp.2627~2634 (2003)
10. Jouanny P, "Environmental and genetic factors affecting bone mass. Similarity of bone density among members of healthy families", Arthritis Rheum, 38, pp.61~67 (1995)
11. Sims AM, "Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes", J Bone Miner Res, 23, pp.499~506 (2008)
12. 김훈, "Association between polymorphisms in Wnt signaling pathway genes and bone mineral density in postmenopausal Korean women", MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 17(5), pp.1064~1070 (2010), LIPPINCOTT WILLIAMS WILKINS
13. Kim JG, "The relationship between Wnt signaling pathway gene polymorphisms and changes in production of Osteoprotegerin and Soluble Receptor Activator of NF-кB by whole blood cells after hormone therapy", J Reprod Endocrinol, 2, pp.102~109 (2010)
14. Kim H, "The relationship between polymorphisms of Wnt antagonists genes and production of Osteoprotegerin (OPG)-soluble receptor activator of NF- кB ligand (sRANKL) by whole blood cells", J Reprod Endocrinol, 4, pp.20~29 (2012)
15. Sturdee DW, "Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health", Climacteric, 14, pp.302~320 (2011)
16. Hassager C, "Nonresponders to hormone replacement therapy for the prevention of postmenopausal bone loss: Do they exist?", Osteoporosis Int, 4, pp.36~41 (1994)
17. Komulainen M, "Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial", J Clin Endocrinol Metab, 84, pp.546~552 (1999)
18. Komulainen M, "Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial", Osteoporos Int, 11, pp.211~218 (2000)
19. Bafico A, "Novel mechanism of Wnt signaling inhibition mediated by Dickkopf-1 interaction with LRP6", Arrow, 2001, pp.3, 683~686
20. Mao B, "Kremen proteins are Dickkopf receptors that regulate Wnt", beta-catenin signaling, 2002, pp.417, 664~667
21. Niehrs C, "Function and biological roles of the Dickkopf family of Wnt modulators", Oncogene, 25, pp.7469~7481 (2006)
22. MacDonald BT, "Bone mass is inversely proportional to Dkk1 levels in mice", Bone, 41, pp.331~339 (2007)
23. Wang FS, "Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats", Bone, 40, pp.485~492 (2007)
24. Anastasilakis AD, "The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis", Clinical Endocrinol, 72, pp.752~757 (2010)
25. Yao W, "Overexpression of secreted frizzled related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects", J Bone Miner Res, 25, pp.190~199 (2010)
26. Gaur T, "Secreted frizzled related protein 1 is a target to improve fracture healing", J Cell Physiol, 220, pp.174~181 (2009)
27. Saika M, "17β- estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α", Endocrinology, 142, pp.2205~2212 (2001)
28. Hofbauer LC, "Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells", Endocrinology, 140, pp.4367~4370 (1999)
29. Bord S, "Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen", Br J Haematol, 126, pp.244~251 (2004)
30. Lee DO, "The relationship between changes in the production of osteoprotegerin (OPG), soluble receptor activator for nuclear factor кB ligand (sRANKL) by whole blood cells and changes in bone mineral density after estrogen-progestogen therapy in postmenopausal women", J Korean Soc Menopause, 13, pp.96~105 (2007)
31. Eghbali-Fatourechi G, "Role of RANK ligand in mediating increased bone resorption in early postmenopausal women", J Clin Invest, 111, pp.1221~1230 (2003)

관련 논문AI추천